Agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome

FIELD: veterinary medicine.

SUBSTANCE: agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome comprises wt % silver nitrate 0.01-0.5, levamisole base 3.0-8.0, ascorbic acid 1.0-12.0 and water for injection - the rest.

EFFECT: antibacterial, immunomodulatory effect, anti-stress, antioxidant effect, and increase in effectiveness of prevention of gastrointestinal diseases in calves with diarrhea syndrome.

10 tbl, 6 ex

 

The technical field to which the invention relates.

The invention relates to veterinary medicine, in particular to the drug for prevention of gastrointestinal diseases of calves with diarrhea syndrome.

The level of technology

Known methods of treatment of gastrointestinal diseases of calves using various means: antibiotics, sulfonamides, electrolytes, vitamins, enzymes, herbs and other, for example, to suppress and prevent the development of putrefactive microflora known methods of antimicrobial therapy: Darina (see Andreev N. L. and other Pharmaco-Toxicological properties Varina // veterinary medicine. 2002. No. 8. - S. 44-45), tehamana (see Rakhmanov I. X. Application tehamana for the treatment and prevention of gastrointestinal diseases of newborn calves: author. thesis Cand. wet. Sciences, Voronezh, 1998),which consists of sacralization and erythromycin, sulfadimidine and glucose, articlenum (see CASCO HP, Mosin C. M., Gamayunov C. M., Kuklin B. N. Effectiveness of recycline in the treatment of gastrointestinal and respiratory diseases in calves, " Dokl. RAAS. 1996. No. 3. - S. 33-34.), the baytril (see Mishchenko C. A., Yaremenko N. A. and other aspects of the pathogenesis of diarrhea of newborn calves. - Veterinary. - 1999. - 9. - S. 20-23.), fluvaccine a daily dose of 20 mg flumadine 1 kg weight of the animal, gentamicin - on the first day, 5 the gentamicin powder per 100 kg of body weight, divided into two doses with an interval of 12 h, in the next 2-4 days - 4, Gentamicin powder per 100 kg of body weight 1 times/day; oxytetracycline at a dose of 20 mg of oxytetracycline per 1 kg of body weight 1 time in three days, but not more than three times (see Medicines veterinary use in Russia / Directory. - M.: Attraversare. - 2011. - 512 S.).

The disadvantages of these drugs are the low efficiency of treatment and prevention of gastrointestinal diseases of calves.

There is a method of treatment and prevention of gastrointestinal diseases in calves and piglets, including oral administration of the drug pentazocin given once daily by blending to loose feed, drink water or milk in doses of 100-500 mg/kg animal body weight (see U.S. Pat. RU # 2427366, IPC A61K 31/00, A61P 31/04, publ. 27.08.2011,).

The disadvantages of this method of treatment and prevention are the appearance in the abomasum of calves dysbacteriosis and inhibiting the activity of beneficial microflora.

There is a method of treatment and prevention of gastrointestinal diseases of newborn calves, which includes the appointment of a bacteriostatic, rehydration and symptomatic means. As an antimicrobial, bacteriostatic and rehydration funds are used pharmaceutical preparation containing wt.%: norsulfazol - 1,624, glucose - 1,69, sodium chloride - 6,23, potassium chloride 0,649, calcium chloride and 0.2. The drug is used orally, pre-dissolve 500 g of the drug in 8 liters of hot water, 2 times a day for three days in a dose of 0.7-1.5 l on the animal and reduce the amount of colostrum in the first day by 50-100%, the second day of 25%. 40 minutes prior to each injection calves give a decoction of oak bark at the rate of 15 g and 1 time per day subcutaneously injected with 20% solution of caffeine-sodium benzoate at a dose of 3 ml (see U.S. Pat. RU # 2437653, IPC A61K 31/00, publ. 27.12.2011 year).

The disadvantage of these drugs is that they can also call in the abomasum of calves dysbacteriosis and to suppress the activity of beneficial microflora.

There is a method of treatment and prevention of gastrointestinal diseases in calves and piglets by oral administration of the drug containing propolis. The product contains alcohol extract of propolis, sodium carboxylmethylcellulose, glucose, distilled water. The proposed drug "Biogel-5 for the treatment and prevention of gastrointestinal diseases in calves and piglets consists of the following components: 20% alcoholic extract of propolis with the content of propolis balm 100 mg/ml - 5, sodium carboxymethylcellulose - 2, glucose - 10 distilled water - 83. The product is a homogeneous, semi-liquid consistency with a slight bottom of the ugly light brown opaque mass with specific propolis odor and sweetish taste. When shaking the precipitate is easily mixed total weight of the preparation, and when heating to 40-45°C, the viscosity of the drug is reduced. The drug is feeding twice daily at a dose of 10-200 ml for 30-40 minutes before drinking milk, colostrum. Therapeutic effectiveness is 98-100 (see U.S. Pat. RU # 2074727, IPC A61K 35/64, publ. 10.03.1997 year).

The disadvantage of this method of treatment and prevention is that it can be used only as an aid.

The known method of prevention of gastrointestinal diseases in calves, including the use of the drug "EVL-Se COMPOSITION, a solution, which is injected animals inside group method with water (milk or its substitute) once a day for 10 days at a dose of 1.0 ml per head. The application of the method allows to reduce the incidence of, reducing recovery time animals to increase average daily gain, helping to accelerate the development of microflora and does not cause side effects. A member of the drug "EVL-Se COMPOSITION" includes ten components of active substances, each of which has wide application in homoeopathic practice: Arsenicumalbum (D10), Lycopodium (D7), Phosphorus (D29), Podophyllum (D7), Veratrumalbum (D7), Colocyntis (D7), Thjaoccidentalis (D7), Vincetoxicum (D3), Echinaceapurpurea (D3), Selenium Se (D5) (see U.S. Pat. RU # 2392951, IPC A61K 36/00, A61K 33/36, A61K 33/00, publ. 27.06.2010,).

The disadvantage of this method profile is Tiki is the duration of treatment, the high cost.

Known methods of treatment of dyspepsia newborn calves, including as a binder and weak disinfectants such preparations are natural and plant origin, as a decoction of yarrow (see shchetkin A. A. Herbal medicine for dyspepsia calves // veterinary medicine. 1975. No. 2. C. 16-18), tincture of gentian and calendula (see Abdurahmanov T. M. Therapeutic efficacy of tinctures of gentian Turkestan and calendula for dyspepsia calves // the Pathology and treatment of ketosis sheep and lambs: Sat. works Samarkand C. agricultural Institute. 1989. - S. 41-43), as well as herbal, for example herbal tea consisting of 1 part oak root and 1 part calamus rhizomes, fruits cherry 3 pieces and blueberries 2 parts (see Polushin Century, Treatment and prevention of newborn calves with dyspepsia / Year / Century Polushin, S. C. Starchenko, G., Shcherbakov // Treatment and prevention of newborn calves with dyspepsia. SPb gawm. - S. Petersburg. - 1999. - S. 31-32), an aqueous extract of chamomile, oak bark for 50,0, St. John's wort and yarrow by 25.0 per 1 liter of water, at a dose of 200 ml 2 times a day for 6-7 days (see Mikulich E. L. Phytotherapy in the prevention and treatment of gastrointestinal diseases of newborn calves // Actual problems of intensive livestock development. Hill, 1998. - S. 324-328).

The disadvantages of these methods of treatment and prevention are the duration of the treatment and not the high efficiency.

There is a method of treatment of gastrointestinal diseases of calves, including feeding of the calves EM-drug "Baikal EM-1 in a mixture with herbal infusion in the ratio of 1:1. This herbal includes based on 100 ml of water, 0.5 g of herb Hypericum perforatum, 0.5 g of meadowsweet herbs, 0.35 g of the herb yarrow, 0.35 g herbs of nettle, 0.2 g rhizomes of bergenia tolstolistnogo, 0.2 g of roots and rhizomes of marsh cinquefoil and 0.15 g of needles, the needles of Scots pine. The mixture is feeding scheme: 1 day - twice in doses of 30 ml and 50 ml; 2nd day - a triple dose of 100 ml; in the following days - five-fold in a dose of 100 ml to clinical recovery (see U.S. Pat. RU # 2381806, IPC A61K 36/00, A61K 35/66, publ. 20.02.2010,).

These and other infusions and decoctions can not be used as the primary means for the treatment of dyspepsia newborn calves due to lack of effectiveness, but only as a means of adjuvant therapy.

The known method of prevention and treatment of dysbacteriosis of young farm animals using probiotic "Sakhabaktisubtill" which promotes immunobiological reactivity of the organism in calves and piglets, improves the absorption of nutritional components of food and has a positive effect on the increase in live weight (see the First Congress of veterinary pharmacologists Russia. - Voronezh 21-2 June 2007: proceedings of the Congress. - Voronezh. - 2007. - S. 459-463).

The disadvantage of this method of prevention is the low efficiency of treatment of animals with diseases of the gastrointestinal tract.

However, the use of probiotics is not always accompanied by positive effects that can be caused by a failed selection used for their preparation strains, technology failure and other causes of reduced quality of drugs. Use in complex therapy with antibiotics probiotics on the basis of living organisms is difficult or impossible. In addition, probiotic preparations have limited spectrum of activity, as they are directed against a small group of agents.

Known therapeutic biological product "Backspacing, including the biomass of the strain Bacillus subtilis 3H (GISC No. 248), while it additionally contains a filler in the following ratio, wt.%: the biomass of the strain Bacillus subtilis (GISC No. 248) - living microbial cells (1-5)×109in 1 ml of solvent 92-95, filler - 5-8 (see U.S. Pat. RU # 2130316, IPC A61K 35/74, C12N 1/20, publ. 20.05.1999 year).

However, it is ineffective against a number of pathogens of acute intestinal infections, for example, caused by bacteria Pseudomonasspp., Streptococcusspp., Enterococcusspp.

There is a method of correction of immune deficiency and prevention of diseases of the gastrointestinal Proc. of the KTA newborn calves. Calves injected subcutaneously antihistamine the serum titer of antibodies to histamine is not lower than 1:256, at a dose of 10.0-15.0 ml on the head, once daily, three times in the 1st, 3rd and 6th days of life. Antihistamines serum [8] is a liquid straw yellow color and contains antibodies against histamine. In addition, the serum contains a number of other biological components, among which the importance of gammaglobulin, ceruloplasmin, lysozyme, and most important of antibodies against histamine with titre not less than 1:256. This drug is produced by hyperimmunization horses gistaglobulina in a specific pattern (see U.S. Pat. RU # 2223786, IPC A61K 39/395, A61P 1/00, A61P 37/00, publ. 20.02.2004).

Selection as a means of treatment of AGS with high titres of antibodies against histamine helps to neutralize the excess of one of the major inflammatory mediators - histamine - animals with gastrointestinal diseases. Increased release of biologically active substances, including histamine, occurs primarily in the intestines, due to the development of degenerative-necrotic and inflammatory processes in the intestinal mucosa after exposure to different damaging agents, including pathogenic bacteria and their toxins.

Excess histamine alters trophic wall of the gastrointestinal tract, increases about Icemist, reduces the barrier and selective function causes a sudden spastic contractions of the intestinal wall, which further upsets the digestive processes. The accumulation of large amounts of histamine in the body of the sick calves is due to the decrease in their activity histaminase, failure histaminergic mechanisms, resulting in more broken metabolism, resulting in lower natural resistance of the organism and the development of immunodeficiency.

The disadvantage of this method is the necessity of strict observance of the doses and schemes of use, as may be allergic effect in the form of anaphylactic shock.

The closest in technical essence and the achieved positive effect and adopted by the authors for the prototype is the drug Agrovit, which includes polivinilpirolidon, silver nitrate and ethyl alcohol, with argovit has a broad spectrum of antimicrobial activity against aerobic and anaerobic microorganisms, including antibiotic-resistant; exhibits virucidal and fungicidal activity; anti-inflammatory effect. Available in the form of concentrated solution, is used in the form of dilute aqueous solutions (see Shkil N. N., Shkil N. A., Burmistrov C. A., Sokolov, M. Y. Antimicrobial St is Ista, pharmacotoxicological characteristics and therapeutic efficacy of the drug Agrovit for gastro-intestinal diseases of calves. - Scientific journal of Kuban state agrarian University, №68(04). - 2011. - C. 1-11).

The drug is used for prevention and treatment of intestinal infections of various etiologies in all species of farm animals and fur-bearing animals. For the prevention of gastroenteritis calves with diarrhea syndrome argovit used in the form of a 0.3% aqueous solution, at the rate of 1-2 ml/kg body weight within 2-5 days depending on the clinical condition. In severe disease, the dose is doubled (see Shkil N. N., Shkil N. A., Burmistrov C. A., Sokolov, M. Y. Antimicrobial properties, pharmacotoxicological characteristics and therapeutic efficacy of the drug Agrovit for gastro-intestinal diseases of calves. - Scientific journal of Kuban state agrarian University, №68(04). - 2011. - C. 1-11).

The disadvantage of this drug is the absence in the composition of immunomodulators.

Disclosure of inventions

The task of the invention is the development of a drug for the prevention of gastrointestinal diseases of calves with diarrhea syndrome, with high efficiency prevention of gastrointestinal diseases of calves, antibacterial, immunomodulatory effects and anti-stress, antioxidant effect, due to the use of biocompatible to the complex of the drug.

The technical result that can be achieved using the present invention is antibacterial, immune modulating action, anti-stress, antioxidant effect and improve the prevention of gastrointestinal diseases in calves with diarrhea syndrome.

The technical result is achieved by using a drug for the prevention of gastrointestinal diseases of calves with diarrhea syndrome, including silver nitrate in the form of a colloidal system of 0.1 to 3.0%, and it further comprises levamisole base, ascorbic acid and water for injections in the following ratio, wt.%:

silver nitrate0,01-0,5
levamisole base3,0-8,0
ascorbic acidof 1.0 to 12.0
water for injectionrest

The entity receiving the drug for prevention of gastrointestinal calves is as follows: the initial substance in wt.%, namely, the silver nitrate from 0.01 to 0.5, levamisole base 3,0-8,0, ascorbic acid and 1.0 to 12.0 and water for injection - the rest is mixed under aseptic conditions and Packed.

Thus, the drug for prevention of gastrointestinal diseases of calves is provided pharmacological action of the drug's components and is defined by the following components.

Bactericidal properties of silver and its compounds have been known since ancient times. Preparations of silver is widely used in medicine and veterinary medicine in 20-40 years of XX century. Chemistry and biochemistry of compounds of silver has advanced significantly. For them found immunomodulating activity, synergistic enhancement of efficiency in the complex of silver with sulfonamides and other drugs (see Y. Ershov A., Islenska N. B. Lobanov F. I., Pletnev So Century. Biotesting of water solutions of drugs silver Paramecium // Application of preparations of silver in medicine. - 1994. - SORAN. - S. 84-88; Bult, A., Klasen, H. B. The characterization of the silver compounds of some sulfanilamide derivates. // Arch. Pharm. - 1978 - P. 855-861).

Silver acts on nucleic acids of bacteria. It is obvious that the attachment of the silver stops the multiplication of germplasm, stabilizing RNA and DNA. This stops the copying of the genetic information necessary for cell multiplication (see Landsdown A. B. G. Silver 1: Its antibacterial properties and mechanism of action // Journal of wound care. - 2002. - N 11(2). - S. 125-130).

Molecular and biochemical basis of antimicrobial activity of silver and its preparations is rather complex and involve the complexing, biochemical and catalytic action of silver on bacterial enzymes, proteins and membrane structures (see Kopeikin Century Century silver-containing Medicinal preparations and their biomedical properties / Application of preparations of silver in medicine. 1993, SB RAMS IKI, S. 36-40; Roshchin, A. C., Ordzhonikidze E. K. Silver - some aspects of exogenetic // labor Hygiene and occupational diseases, 1984, No. 10, S. 25-28).

The positive aspect is a big difference in the toxicity of silver compounds to lower forms of life (protozoa, bacteria, viruses, and so on), and for higher organisms (animals, people), reaching 5-6 orders of magnitude (100 thousand to 1 million times) (see Kopeikin Century Century silver-containing Medicinal preparations and their biomedical properties / Application of preparations of silver in medicine. 1993, SB RAMS IKI, S. 36-40). That is, the concentration of compounds of silver, lethal for microorganisms, practically harmless to animals and humans.

Biological functions of ascorbic acid, i.e. vitamin C, are part of the redox processes, the regulation of carbohydrate metabolism, clotting of the blood, stimulation of hematopoiesis, the formation of steroid hormones in the adrenal glands, the normalization of the capillary permeability (see Melnychenko Century. And. Antioxidants in veterinary medicine: new opportunities. Veterinary clinic. - 2006 No. 7). One of the main properties of ascorbic acid is its ability to redox transformations. Ascorbic acid is able to be oxidized to dehydroascorbic acid and, thus, together with her she is a redox system, losing and consolidating electrons and protons. Vitamin C regenerates vitamin E, but when it is oxidized (see YiO. S., Han D., Shin, H. Q. Synergistic antioxidative effects of tocopherol and ascorbic acid in fish oil (lecitin) water system. J. Am. Oil Cyem. Soc. - 1991; 5(8). - C. 881-883). Supplements of vitamin C improves immune response by maintaining the level of vitamin E in the blood and tissues, vitamin E is a strong stimulator of the immune system (See. Bendich, A., D Apolito R., Gabriel E., I. J. Machlin Modulation of the immune system function of guinea pigs by dietary vitamin E and following exposure to oxygen // Fed. Proc. - 1983. - 42. - P. 923).

Vitamin C restores Selenite to elemental selenium and elemental sulfur and selenium are easily reduced, forming sulfides and selenides containing two or more atoms of sulfur and selenium. Selenocysteine proteins by electron transfer can connect with elemental selenium with the formation of selenium-containing linkages.

Levamisole (Levamisolum) - 2,3,5,6-tetrahydro-6-phenylimino-zo-[2,1-b]-thiazole hydrochloride. White amorphous or crystalline powder. Easily soluble in water. Initially, the drug was offered to the cooperating sedative. In the study of anthelmintic action of levamisole was found that it increases the overall resistance of the body and can be used as a tool for immunotherapy. Experiments on isolated cells and the monitoring of healthy and sick animals have shown that the drug can restore the changed functions of T-lymphocytes and phagocytes and because of his demominations effect can regulate cellular mechanisms of the immune system. More detailed studies showed that levamisole, selectively stimulating regulatory functions of T-lymphocytes, can function as an immunomodulator, could strengthen weak cellular immune responses, to weaken strong and not to act normal reaction. In connection with these properties levamisole has been proposed for the treatment of various diseases, the pathogenesis of which the value of disorders of immunogenesis: primary and secondary immunodeficiency, autoimmune disease, chronic and recurring infections, tumors and other Levamisole as an immunostimulating drug may be effective in the treatment of various diseases (See. Mashkovsky memorial plaques - M38 Medicines: In 2 volumes. So 2. - 11th ed. wiped. - M.: Medicine, 1988. - 576 c. ISBN 5-225-00036-3).

Levamisole is a highly effective anthelmintic used zheludochno the gastrointestinal and pulmonary nematodes. The drug causes an increase in the number of both T-and B-lymphocytes, the titers of natural antibodies and an antibody productions in the intact animals. The data obtained showed that levamisole in the intact animals mainly stimulates cell-mediated immunity. It causes rapid effect: within a day, the number of T-lymphocytes is increased in 2 times in comparison with the control animals. The spontaneously infected in these days of levamisole in the dose of 10 mg/kg on ADV caused increased levels of T-lymphocytes in 5 times. Increasing the activity of T-lymphocytes, coming under the influence of levamisole, obviously, plays an important role in the ability of the drug to increase the immunobiological properties of the organism (see Daugeliene E. H. Filippov centuries Immune status and ways of its correction in the worm farm animals. - M: VO "Agropromizdat". - 1991. - 188 S.).

As solvent selected water because all the components of the drugs are water-soluble compounds.

A brief description of the drawings and other materials

Table 1 provides a drug for prevention of gastrointestinal diseases of calves with diarrhea syndrome, antimicrobial activity of the drug for prevention of gastrointestinal diseases of calves.

In table 2, the same parameters of acute toxicity of the drug for prevention of gastrointestinal illness is her calves after a single intragastric administration (mg/kg DW) (n=10).

In table 3 is the same, the dynamics of body weight of white rats during repeated administration of the drug for prevention of gastrointestinal diseases of calves.

In table 4, the same, hematological parameters of mice (n=10).

In table 5, the same biochemical indices of blood serum of mice (n=10).

In table 6 is the same, the comparative effectiveness of different regimens of calves.

In table 7 is the same, hematological and immunological parameters of blood of calves (n=8).

In table 8, the same comparative efficacy of prevention calves (n=10).

In table 9 is the same, the content of total protein and protein fractions of the blood serum of calves (n=10).

In table 10, the same biochemical parameters of blood of calves (n=10).

The implementation of the invention

Examples of specific implementation receiving the drug for prevention of gastrointestinal diseases of calves with diarrhea syndrome.

In the structure of diseases of calves in the early postnatal period in the first place is occupied by dysfunction of the digestive system, clinically manifested by diarrhea, contributing to the development of severe dehydration, toxemia, immunodeficiencies, metabolic disorders.

Etiopatogenetyczny lesions of the digestive system show considerable polymorphism, including a wide range of different factors, including gene is political, physiological, hygienic and infection. Mass violations of the digestive functions, and is clinically manifested by diarrhea, register at 70-100% of newborn calves by the end of the first day after birth. Sick calves refuse colostrum, constantly lie, quickly comes dehydration, intoxication, anophthalmia sharply reduced tone.

The death of newborn calves, usually occurs 2-5 day or 7-10 days. Usually dies from 15 to 55% of newborn calves.

Example 1. The drug for prevention of gastrointestinal diseases of calves is prepared as follows: the initial substance in wt.%, namely, the silver nitrate 0,001, levamisole base 2,0, ascorbic acid 0.5 and water for injection - the rest are mixed under aseptic conditions and Packed.

Result: the study of antimicrobial action of the drug show that the concentration of the drug is not sufficiently strong bactericidal action.

Example 2. The product is prepared analogously to example 1, but the original substance in wt.%, take in the following proportions, namely, the silver nitrate is 0.01, levamisole base 3,0, ascorbic acid 1.0, and water for injection - the rest are mixed under aseptic conditions and Packed.

Result: the study of antimicrobial action of the drug show that the concentration of the drug, about which provides a strong bactericidal action.

Example 3. The product is prepared analogously to example 1, but the original substance in wt.%, take in the following proportions, namely, the silver nitrate 0,1, levamisole base of 7.5, ascorbic acid 5.0, and water for injection - the rest are mixed under aseptic conditions and Packed.

Result: the Study of antimicrobial action of the drug show that the concentration of the drug, exhibits strong bactericidal action.

Example 4. The product is prepared analogously to example 1, but the original substance in wt.%, take in the following proportions, namely, the silver nitrate is 0.5, levamisole base 8,0, ascorbic acid 12,0 and water for injection - the rest are mixed under aseptic conditions and Packed.

Result: the Study of antimicrobial action of the drug show that the concentration of the drug, exhibits strong bactericidal action.

Example 5. The product is prepared analogously to example 1, but the original substance in wt.%, take in the following proportions, namely, the silver nitrate is 0.8, levamisole base 9,0, ascorbic acid 15,0, and water for injection - the rest are mixed under aseptic conditions and Packed.

Result: the Study of antimicrobial action of the drug show that the concentration of the drug, showing the side effects of the drug, namely suppression in the abomasum of calves useful life is th microflora.

Thus, the best product is the product obtained according to examples 2, 3, 4.

Example 6. Determination of antimicrobial drug action.

Determination of antimicrobial activity of the drug for prevention of gastrointestinal diseases calves carried out by the method of diffusion in agar according to the State Pharmacopoeia of the Russian Federation, XII edition. - Moscow. - 2010. - 600 C. the Method is based on the assessment of the inhibition of growth of test microorganisms defined concentrations of the tested tools. To test antimicrobial activity using 24-hour test-cultures grown on stubble mesopatamia agar (MPA). Microbial culture with MPA wash 2-3 milliliters of saline solution and prepare a suspension containing 500 million microbial cells in 1 ml of standard turbidity. On the surface of the agar in the Petri dish of the same diameter make seeding a continuous lawn of standard suspensions used the test cultures. For this purpose, 2 ml of the suspension was placed in a Petri dish, suspended evenly spread over the surface, and the excess suspension is completely removed. All Petri dishes placed in a thermostat at 37°C for 18-20 hours horizontally to obtain a circular zones of inhibition of growth of microorganisms. After incubation the diameter of zones of inhibition of growth is measured using a millimeter ruler.

In the experiment using the test culture: 1) Staphlococcusaureus (209) (ATSS 25923); 2) Escherichiacoli 675; ATS 25922) 3) Pseudomonasaeruginosa (ATSS 27853). The results of researches are presented in table 1.

The results of microbiological studies show that the drug for prevention of gastrointestinal diseases of calves has a bacteriostatic action against gram-positive bacteria of the genus Staphylococcus and gram-negative rods Escherichiacoli. Against spore-forming Bacillus kind of Pseudomonasaeruginosa has a strong germicidal effect. This indicates a wide spectrum of antibacterial action of the drug for prevention of gastrointestinal diseases.

Thus, the most optimal is 10% concentration of the drug, showing a strong bactericidal action.

For Toxicological studies and evaluation of the action of the drug for prevention of gastrointestinal diseases calves take the following ratio of components, wt.%:

silver nitrate0.1
levamisole base7,5
ascorbic acid5,0
water for injectionrest

Toxicological studies p is eparate for the prevention of gastrointestinal diseases of calves. To determine the lethal doses of the drug used clinically healthy white mice weighing 20-22 g, studies are carried out according to the "guidelines for the Toxicological evaluation of new drugs for the treatment and prevention of non-contagious diseases of animals" (Institute of non-contagious diseases of animals, 1987). The active ingredient of the drug is a combination of silver nitrate, levamisole base and ascorbic acid. The method of administration selected intragastric because this drug is designed for oral administration of agricultural animals. Table 2 presents research data on acute toxicity of the drug for the treatment and prevention of gastrointestinal diseases of calves.

When analyzing the results of determination of the acute toxicity of the drug for prevention of gastrointestinal diseases calves found that after intragastric administration of its LD50for white mice is 351,25 mg/kg of body weight, that has allowed to carry the drug to the III class of hazard - moderately hazardous substances (GOST 12.1.007-76 Classification and General safety requirements"). The symptoms were similar and were manifested by agitation, weakness. These symptoms see different animals from 20 to 120 minutes.

Chronic toxicity of the drug for prevention of gastrointestinal diseases calves estimate on what elih outbred rats-females (n=30) at its multiple oral dose, 1/50 LD50. The use of the drug for prevention of gastrointestinal diseases of calves does not cause significant changes in the clinical status of white rats: behavior, grooming, appetite, respiratory rate in rats during the period of use of the drug, and within weeks of observation after the cessation of injection were normal. Deaths of Wistar rats (females not registered, changes in body weight experimental and control animals, no significant differences (table 3).

To assess the impact of the drug for prevention of gastrointestinal diseases calves on hematological and biochemical parameters using laboratory white mice, which were divided into four groups (n=10). Animals of the first group administered intragastric saline, they serve as a control. The mice of the second, third and fourth groups administered intragastrically the test drug for the prevention of gastrointestinal diseases of calves at doses of 10, 30 and 50 mg/kg body weight, respectively. Three days after the drug gets the blood by decapitate for hematological and biochemical studies. The results are shown in tables 4, 5.

Analyzing the obtained results point out that significant changes in the blood of animals to which the drug is administered to prevent gastro-Ki is echnik diseases of calves, compared to the control is not marked. The hemoglobin level, number of erythrocytes and leukocytes is within physiological values for this species.

Table 5 shows the results of biochemical studies of blood serum of mice.

Analyzing the results of biochemical studies it can be noted that significant changes in the blood of animals who enter drug for the prevention of gastrointestinal diseases of calves at doses of 10 and 20 mg/kg, compared with the control is not marked. White mice that received the drug for prevention of gastrointestinal diseases of calves at a dose of 50 mg/kg of body weight in blood serum, the increase in the activity of Alt and AST, respectively 16.2 and 13.5%, the increase of amylase - by 13.7%, minor hypoproteinemia and increased concentrations of total and direct bilirubin, respectively 16.1 and 21.9%. Changes caused by the high dose of the drug for prevention of gastrointestinal diseases of calves, but at the same time, these values fall within the boundaries of the norm for this species.

The effectiveness of the drug for prevention of gastrointestinal diseases calves define in scientific production experiments in terms of the economy, long prone to gastrointestinal bolezn is m, due to the health effects associations of pathogenic and conditionally pathogenic microflora in the background of violations of conditions and feeding pregnant cows and calves.

In the experience of use of newborn calves black-motley breed at the age of 2-10 days. According to the principle of analogues of newborn calves with an initial signs of dyspepsia formed 3 groups of animals (n=10). Conditions and feeding calves in all groups was the same. Calves appoint half-starved diet, skipping the next two feeding colostrum and replacing them with saline solution. In the next feeding is feeding reduced by 40% portion of milk filling volume giving saline 15 minutes before feeding. All experimental animals for removal of intoxication and improve parenteral nutrition is administered reopoliglyukin with glucose intravenous dose of 5 ml per kg body weight per day, isotonic sodium chloride solution intravenously at a dose of 50-100 ml per animal. For the animals of the first group, the regimen includes a drug for prevention of gastrointestinal diseases of calves on the basis of silver in the form of a 0.1% aqueous solution, at the rate of 1.5 ml/kg body weight within 2-4 days depending on the clinical condition. In the second group of calves injected subcutaneously drug "Baytril 5% solution for injection in a dose of 1 ml per 20 kg mass of the LM is now (2.5 mg enrofloxacin per 1 kg of weight) in 3-5 days. Sick calves third group assign levomycetin orally 2 times a day in a dose of 10 mg/ kg weight of the animal. All the drugs used to the disappearance of clinical symptoms of dyspepsia.

Therapeutic efficacy set, given the number of recovered calves, as well as the duration and severity of disease (table 6).

As a result of the research the greatest therapeutic effect in the prevention of cases of dyspepsia calves installed in the first group, where the treatment of sick calves included the drug for prevention of gastrointestinal diseases of calves on the basis of silver. This group has the lowest average duration of treatment is 3.8±0,62 days, which is less than the second and third groups 17.4 and 26.9 percent, respectively.

With equal therapeutic efficacy of prophylaxis animals of the second and third groups, the duration was different and respectively 4,6±0,71 and 5.2±0.51 days.

Thus, prevention of patients with dyspepsia calves with use of the drug for prevention of gastrointestinal diseases of calves, reopoligliukina with glucose and isotonic sodium chloride solution, gives 90% therapeutic effect superior to the efficacy of therapy using Baytril 5% and levomicetina.

To identify preventive efficiency the efficiency of the drug for prevention of gastrointestinal diseases of calves on the principle analogues formed three experimental and one control group of calves three days of age black-motley breed of 8 animals in each group. Calves first, second and third experimental groups orally administered drug for prevention of gastrointestinal diseases, respectively, at doses of 1.0, 1.5 and 2.0 ml/kg body weight for three days. Animals of the control group the drug for prevention of gastrointestinal diseases calves do not apply. In the case of animal diseases are treated with medications that are applied in this sector, Trimerized inward at the rate of 1 tablet per 15 kg body weight of the animal. The daily dose is administered in two doses at 12-hour intervals. Prevention is carried out before the disappearance of clinical signs of disease and in the next two days, + 4% solution of gentamicin intramuscularly twice a day with an interval of 10-12 hours at a dose of 0.5 cm310 kg weight of the animal twice a day, + decoction of oak bark 150-200 ml / day). The results are shown in table 7.

As a result of researches it is established that the blood of the animals first, second and third groups in comparison with the calves of the control group increased the number of erythrocytes, respectively, 6.1, and 11.0 to 15.5%, leukocytes, respectively 8.2, and 15.2%. Statistically significant increase in the concentration of hemoglobin in animals of the experimental groups, respectively, 10.3, 16,7, and 14.5%.

The use of the drug for prevention of Zheludok is about-intestinal diseases calves had a positive impact on the total concentration of albumin and globulin, bactericidal activity of blood serum and the enzymatic activity of lysozyme. So, in the blood of animals first, second and third group SEX in the comparison data "control" was more respectively 19.6, 32,8 and 34.4%.

Prophylactic efficacy threefold use of the drug for prevention of gastrointestinal diseases of calves at a dose of 1.0 ml/kg body weight was 75%, 1.5, and 2.0 ml/kg - 87,5%).

Comparative evaluation of treatment regimens for using the developed drug for the prevention of gastrointestinal diseases calves spend 30 calves 2-5 days of age, which are divided by type analogues in three equal groups. The first group of control, formed from clinically healthy calves. The second and third group includes animals with primary clinical signs of dyspepsia: not too rapid defecating, poop liquid, suppression of the General condition, weakening or loss of appetite, increased respiration and heart rate, body temperature within normal limits. When early symptoms of the disease is passed two or three regular feeding. To prevent dehydration during minor illness used the oral method of rehydration, using a solution of ringer-Locke dose of 200-300 ml If the calf has improved in each subsequent feeding amount of colostrum increase 20-300 ml Trimerized tablets imposed at the rate of 1 tablet per 15 kg body weight of the animal. The daily dose is administered orally in two doses at 12-hour intervals. Treatment prior to the disappearance of clinical signs of disease and in the next two days. Subcutaneously injected Baytril 5% injectable solution in the following a dose of 1 ml per 20 kg weight of the animal (2.5 mg enrofloxacin per 1 kg of body weight) once a day for 3-5 days. Enrofloxacin, which is part of the drug, belongs to the group of fluoroquinolones, has a broad spectrum antibacterial and antimycoplasmal actions, inhibits the growth and development of gram-positive and gram-negative bacteria. Calves third group additionally used a drug for the prevention of gastrointestinal diseases of calves at a dose of 1.5 ml/kg animal body weight orally for 3-5 days.

In the process of observation of the animals consider their General condition, indicators of body temperature, pulse and respiration, the severity of external symptoms, identify methods of inspection, palpation, percussion and auscultation, the timing of clinical recovery and the percentage of preservation. The results of these studies are presented in table 8.

The purpose of the complex therapy of calves suffering from simple indigestion, affect the General condition of the animals, they uluchshit the appetite, fecal mass was compacted breathing and heart rate returned to normal, no signs of dehydration. Inclusion in the regimen developed drug for the prevention of gastrointestinal diseases calves allowed to reduce the duration of treatment by 30.4%, with an average daily gain of the animals in this group was greater by 20.7 g than in animals of the second group and is practically not inferior performance of the calves of the control group.

Before the start of the experiment, after 15 and 30 days after the start of treatment, the animals of each group take blood for biochemical studies.

In the serum of calves determine the total protein content refractometric method and protein fractions - turbidimetrically values () method, the concentration of total lipids from sulfurospirillum reagent - Chaneru-Kirsch (statement of L. C. Orlova), the content of total serum cholesterol is by the reaction of Liberman-Burchard (modification ilca), table 5.

When defining indicators of the antioxidant defense system of the body and of free radical oxidation products used standard methods (Kondrakhin I. P., Arkhipov A. C. Methods of veterinary laboratory diagnosis / Reference. - M.: Kolos C. - 2004. - 520 S. Determination of total antioxidant activity of the blood (AAO) is done using a standard set of react is Bob "Total Antioxidant Status of the company Randox.

On the influence of the drug for prevention of gastrointestinal diseases of calves to increase the total resistance, the normalization of some physiological processes in animals are judged by results clinical observations, to improve the functional status of the antioxidant system of the organism and reduce the accumulation of toxic products of lipid peroxidation.

Prevention of sick calves increases total protein content in animals of the second and third groups 30 days after the beginning of supplementation, respectively 12.1 and 13.3%. In the body's total protein performs the following functions: participates in blood clotting, maintains the constancy of the pH of the blood, carries out the transport function (transfer of lipids, bilirubin, steroid hormones to the tissues and organs involved in immune responses (table.9).

30 days after the beginning of the prevention of animals with signs of diarrhea using the scheme developed drug for the prevention of gastrointestinal diseases calves levels of gamma-globulin fraction increased from 22.0±2.4% to 34,5±3,2% in calves compared groups with standard scheme - from 21.5±3.1 per cent to 31.1±2.6 per cent. This suggests that immunological changes more when using the developed drug for the prevention of gastrointestinal bolezn the th calves.

The results of biochemical studies are presented in table 10.

From the table it is seen that the concentration of total lipids in calves to prevention was below the physiological norm and is accordingly 2,16±0,08 2.24±0.04 g/l, which may be due to inhibition of enzyme systems resynthesis of triglycerides in the intestinal wall. 15 days after the beginning of the prevention of the concentration of total lipids in animals of the second and third groups reached the bottom border of norm. Through 30 days after the beginning of the prevention of the concentration of total lipids in animals of the third group treated with a drug for the prevention of gastrointestinal diseases calves reached values of "control" and was higher in comparison with the data of the animals of the second group by 29.3%. at its diseases. Similar performance metrics animals received and determining the concentration of cholesterol.

It is known that the biological role of catalase is the degradation of the hydrogen peroxide formed in the cells as a result of several flavoprotein oxidase (xanthine oxidase, glucose oxidase, monoamine oxidase, and others), and to ensure effective protection of cellular structures from destruction under the action of hydrogen peroxide. In the observation period mark stable growth dynamics of catalase activity in calves the second the third group, moreover, this figure was higher in the animals of the third group 15 days after the beginning of prophylaxis by 8.9% in 30 days - by 13.2% in comparison with data of the second experimental group.

It is also known that one of the leading pathogenetic mechanisms in the development of pathology is oxidative stress, which characterizes the indicators which are the AAO and MDA in blood. The average level of total antioxidant activity of the blood to prevent the calves from the second experimental group was 0,98±0.24 mmol/l, the third experimental group - 0,96±0.12 mmol/l, which was lower than "control", respectively 20.3% and 21.9%, while the mean values of MDA, respectively 24,17±2,12 nmol/ml and 23,98±1,42 nmol/ml, which was significantly higher than control values. Comprehensive preventive treatment of sick calves promotes increased total antioxidant activity of the blood and a decrease in the concentration of MDA, and more intensively these processes are the animals of the third group, which in the scheme of prevention was included developed a drug for prevention of gastrointestinal diseases of calves. Thus, the performance of the AAO in the blood of the calves of the third group were significantly higher at 14.9% in comparison with data of the second experimental group, and the concentration of MDA - 25.4% lower.

Studies show that the inclusion in the regimen developed preparation is for the prevention of gastrointestinal diseases calves stabilizes blood lipids and cholesterol, activates the processes of lipid peroxidation, reduces the concentration of malondialdehyde, which reduces the permeability of cell membranes and enhances the natural resistance of animals.

Thus, the present invention in comparison with the prototype and other known technical solution has the following advantages:

- improvement of preventive and curative effectiveness;

- increase in the overall resistance of the organism of animals;

- increase of antioxidant action.

Table 1
The concentration of the drug, %The diameter of growth inhibition of the test cultures of microorganisms mm
S. aureusE. coliP. aeruginosa
10,80,70,5
35,24,34,6
512,69,411,7
1014,2 10,812,6

Table 2
AnimalThe toxicity parametersSLD50
MTDLD0LD16LD50LD84LD100
White mouse120,11to 21.91270,67351,25462,12565,32±0,006

Table 3
GroupDays of research
Before drug administration102030
Experienced101,2119,5135,4146,2
Control to 102.3120,1136,7145,9

Table 4
GroupDose, mg/kg of LWErythrocytes, million/µlColor metric unitsHemoglobin, g/lLeukocytes, thousand/ál
control-7,8±0,71,04±0,09155, 2mm±6,58,3±1,1
1 test107,9±1,31,05±0,04to 158.4±7,28,0±0,8
2 experimental307,6±1,11,08±0,07159,5±8,49,8±1,2
3 experimental507,1±0,51,12±0,12of 156.6±9,59,1±1,8
Note: P≤0,05

Table 5№ p/pIndicatorsEd.Group, dose, ml/kg1234control1020501Alanine aminotransferaseU/l22,3±0,2422,9±0,2622,9±0,2626,6±0,32∗2Aspartate aminotransferaseU/l80,1±2,2to 82.9±2,4to 82.9±2,1of 92.6±2,6∗3AmylaseU/l23,96±1,420.59±1,820.59±1,827,77±1,6∗4Lactatedehydrogenase105,32±15,694,20±16,296,20±16,2schedule rate is now 99.14±14,35CreatinekinaseU/l334,5±11,6332,7±21,4336,7±21,4368,6±16,76UreaMol/lto 9.91±1,1211,09±1,0811,09±1,0811,64±1,167Albuming/l33,0±1,234,6±1,335,6±1,325,7±1,1∗8Total proteing/l57.20±1,1058,02±1,1556,02±1,1553,80±0,94∗9Glucosemmol/l9,73±1,1611.82±1,2411.82±1,24 7.76±1,3210Total bilirubinΜmol/l9.40±0,42a 9.60±0,62or 10.60±0,6211,20±0,54∗11Direct bilirubinΜmol/l1,50±0,021,44±0,041,42±0,041,92±0,01∗12Cholesterolmmol/l1,7±0,31,6±0,51,7±0,41,6±0,2Note: ∗ - p≤0,05

Table 6
IndicatorsGroup
123
The number of animals, goal101010
Recovered, goal9 88
Palo goal122
The duration of prophylaxis, days3,8±0,624,6±0,715,2±0,51
Therapeutic effectiveness, %908080

Table 7
IndicatorsGroup of animals, dose, ml/kg
4-control1-1,02-1,53-2,0
Before the introduction ofAfter introductionBefore the introduction ofAfter introductionBefore the introduction ofAfter introductionBefore the introduction ofAfter introduction
Erythrocytes, 1012/l8,12±1,127,55±0,858,65±0,828,12±0,72being 9.61±0,567,42±0,459,12±0,35
Hemoglobin, g/lto 96.6±3,34to 98.6±3,4595,5±2,31by 109.9±2,65∗95,4±3,25118,4±3,75∗to 96.6±4,32115,3±4,54∗
Leukocytes, 109/l5,7±0,515,6±0,555,8±0,626,1±0,545,6±0,456,6±0,575,2±0,256,6±0,48
Total protein, g %58,3±2,458,3±1,858,6±1,661,4±1,557,8±2,564,2±1,7∗58,4±2,464,1±1,4∗
BASK, %27,32±2,728,61±4,727,52±3,4 30,5±3,327,54±2,433,6±2,227,25±2,433,5±3,5
FOREPLAY, %7,4±2,68,2±3,37,5±2,610,2±1,97,3±1,612,2±2,77,8±2,812,5±4,1
Sore calves, goal7211
Prophylactic efficacy, %-7587,587,5
Note: ∗ - p≤0,05

Table 8
IndicatorsGroup
123
Live weight to prevention, kg 31,2±0,6230,4±0,4830,6±0,83
The live weight of 30 days, kg44,1±0,8642,6±1,1243,2±1,16
The increase in live weight, kg12,9±0,9212,2±1,0612,8±1,12
Average daily gain, kg430,0406,7426,7
The duration of prophylaxis, DN-4,6±0,243,2±0,32
Safety, %10090100

Table 9
Time studiesGroupTotal protein, g/lProtein fraction, %
albuminalpha-globulinsbeta-globulins gamma globulins
To prevent172,4±1,732,4±2,325,4±1,29,3±2,232,9±1,8
261,6±1,8∗38,7±2,3∗29,2±1,610,6±1,821,5±3,1∗
362,8±1,2∗38,6±1,5∗28,8±1,310,6±1,722,0±2,4∗
After 15 days171,6±2,131,b±1,825,9±1,710,2±1,632,3±2,2
266,5±1,834,7±1,928,3±1,411,2±2,725,8±1,6∗
367,9±1,634,1±1,227,9±1,210,4±2,327,6±2,1
After 30 days173,2±2,330,4±2,424,9±0,710,4±2,534,3±2,3
270,1±2,132,5±1,825,5±2,310,9±1,931,1±2,6
372,4±1,930,5±2,125,2±2,29,8±1,934,5±3,2
Note: ∗ - P≤0,05

Table 10
GroupIndicatorsTime studies
Before the treatmentAfter 15 daysAfter 30 days
ControlTotal lipids, g/l4,62±0,064,67±0,044,82±0,05
Cholesterol, g/l0,92±,14 0,96±0,160,94±0,14
The activity of catalase, mkat/l20,2±0,5420,1±0,5220,6±0,56
AAO, 34 ol/l1,23±0,131,22±0,161,26±0,14
MDA, nmol/mlare 11.62±1,2511,93±1,3512,06±1,34
1 testTotal lipids, g/l2,16±0,08∗2,52±0,02∗3,36±0,06∗
Cholesterol, g/l0,48±0,18∗*0,52±0,16∗0,65±0,17
The activity of catalase, mkat/l10,2±0,32∗16,4±0,48∗18,5±0,31∗
AAO, 34 ol/l0,98±0,241,02±0,091,09±0,15
MDA, nmol/ml24,17±2,12∗on 20, 23±1,32∗16,12±1,2∗
2 experimentalTotal lipids, g/l2,24±0,04∗3,16±0,08∗4,75±0,07
Cholesterol, g/l0,47±0,16∗0,61±0,12∗0,92±0,18
The activity of catalase, mkat/l9,6±0,32∗17,8±1,1221,3±0,65
AAO, 34 ol/l0,96±0,121,25±0,081,28±0,04
MDA, nmol/ml23,98±1,42∗19.14 per±1,35∗12,02±1,92
Note: ∗ - P≤0,05

Literature

1. Abdurahmanov T. M. Therapeutic efficacy of tinctures of gentian Turkestan and calendula for dyspepsia calves // the Pathology and treatment of ketosis sheep and lambs: Sat. works Samarkand C. agricultural Institute. 1989. - S. 41-43.

2. Aleksin M. M. Comparative prophylactic efficacy of Interamericana and Lactobacterin for dyspepsia newborn calves: author. dis. Kida. Vet., Sciences: 16.00.01 / Vitebsk state Academy. veterinarian medicine. In tabs, 1996. - 18 S.

3. Andreev N. L. and other Pharmaco-Toxicological properties Varina // veterinary medicine. 2002. No. 8. - S. 44-45.

4. Daugeliene E. H. Filippov centuries Immune status and ways of its correction in the worm farm animals. - M: VO "Agropromizdat". - 1991. - 188 S.).

5. Ershov, Y. A., Islenska N. B. Lobanov F. I., Pletnev So Century. Biotesting of water solutions of drugs silver Paramecium // Application of preparations of silver in medicine. - 1994.- SOLEMN. - S. 84-88.

6. CASCO HP, Mosin C. M., Gamayunov C. M., Kuklin B. N. Effectiveness of recycline in the treatment of gastrointestinal and respiratory diseases in calves, " Dokl. RAAS.1996. No. 3. - S. 33-34.

7. Kondrakhin I. P., Arkhipov A. C. Methods of veterinary laboratory diagnosis / Reference. - M.: Kolos C. - 2004. - 520 S.

8. Kopeikin Century Century silver-containing Medicinal preparations and their biomedical properties / Application of preparations of silver in medicine. 1993, SB RAMS IKI., S. 36-40.

9. Medicines veterinary use in Russia / Directory. - M.: Attraversare.- 2011. - 512 S.

10. Manoukian, S. H. prevention and Treatment of dyspepsia calves drug JACQUES: author. dis. Kida. wet. Sciences. Yerevan. - 1994. - 19 S.

11. Mashkovsky memorial plaques - M38 Medicines: In 2 volumes. So 2. - 11th ed. wiped. M.: Medicine, 1988. - 576 c. ISBN 5-225-00036-3

12. Melnichenko Century. And. Antioxidants in veterinary medicine: but what's possible. Veterinary clinic. - 2006, No. 7.

13. Mikulich E. L. Phytotherapy in the prevention and treatment of gastrointestinal diseases of newborn calves // Actual problems of intensive livestock development. Hill, 1998. - S. 324-328.

14. Main gg Application of sporobacterin liquid to prevent dyspepsia newborn calves / Year, Mihin // proceedings of int. proc. - Spbguvk. 1996. - S. 17.

15. Mishchenko C. A., Yaremenko N. A. and other aspects of the pathogenesis of diarrhea of newborn calves.- Veterinary science. - 1999. - 9. - S. 20-23.

16. Nozdrin, A. Council-4 - effective means of treatment in calves dyspepsia / Year A. Nozdrin, A. I. Lilac, Century, Kostroski // New vet.the preparations. - Spbguvk. 1997. No. 3. - S. 5.

17. The first Congress of veterinary pharmacologists Russia. - Voronezh, June 21-23, 2007: proceedings of the Congress. - Voronezh. - 2007. - S. 459-463.

18. Polushin Century, Treatment and prevention of newborn calves with dyspepsia / Year / Century Polushin, S. C. Starchenko, G., Shcherbakov // Treatment and prevention of newborn calves with dyspepsia. SPb gawm. - S. Petersburg.- 1999. - S. 31-32.

19. Rakhmanov I. X. Application tehamana for the treatment and prevention of gastrointestinal diseases of newborn calves: author. thesis Cand. wet. Sciences. - Voronezh, 1998.

20. Roshchin, A. C., Ordzhonikidze E. K. Silver - some aspects of exogenetic // labor Hygiene and occupational diseases, 1984, No. 10, S. 25-28.

21. Shkil N. N., Shkil N. A., Burmistrov Century, The., Sokolov M. Y. Antimicrobial properties, pharmacotoxicological characteristics and therapeutic efficacy of the drug Agrovit for gastro-intestinal diseases of calves.- Scientific journal of Kuban state agrarian University, №68(04). - 2011. - C. 1-11.

22. Shchetkin A. A. Phytotherapy of predispose calves // veterinary medicine. 1975. No. 2. C. 16-18.

23. BendichA., D ApolitoP., GabrielE., Machlinl. J. Modulation of the immunesystem function of guinea pigs by dietary vitamin Eand C followingexposure to oxygen // Fed. Proc. - 1983. - 42. - P. 923.

24. Bult, A., Klasen, H. B. The characterization of the silver compounds of some sulfanilamide derivates. //Arch. Pharm. - 1978 - P. 855-861.

25. Landsdown A. B. G. Silver 1: Its antibacterial properties and mechanism of action // Journal of wound care. - 2002. - N 11(2). - S. 125-130.

26. YiO. S., Han D., Shin, H. Q. Synergistic antioxidative effects of tocopherol and ascorbicacid in fish oil (lecitin) water system. J. Am. Oil Cyem. Soc. - 1991; 5(8). - C. 881-883.

27. Patent RU No. 2427366 IPC A61K 31/00, A61P 31/04, publ. 27.08.2011,

28. Patent RU No. 2130316, IPC A61K 35/74, C12N 1/20, publ.20.05.1999

29. Patent RU No. 2437653, IPC A61K 31/00 publ. 27.12.2011,

30. Patent RU No. 2260437, IPC A61K 33/04, A61P 43/00 publ. 20.09.2005,

31. Patent RU No. 2074727, IPC A61K 35/64, publ. 10.03.1997,

32. Patent RU No. 2223786, IPC A61K 39/395, A61P 1/00, A61P 37/00, publ. 20.02.2004

33. Patent RU No. 2392951, IPC A61K 36/00, A61K 33/36, A61K 33/00, publ. 27.06.2010,

34. Patent RU No. 2381806, IPC A61K 36/00, A61K 35/66, publ. 20.02.2010,

The drug for prevention of gastrointestinal diseases of calves with diarrhea syndrome, including silver nitrate, characterized in that it further comprises levamisole base, ascorbic acid and water for injects the th in the following ratio of components, wt.%:

silver nitrate0,01-0,5
levamisole base3,0-8,0
ascorbic acidof 1.0 to 12.0
water for injectionrest



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.

EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.

4 tbl, 3 ex

FIELD: packaging industry.

SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.

EFFECT: invention enables to extend the shelf life of the probiotic product.

13 cl, 1 dwg, 1 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate.

EFFECT: novel compounds have an easily weighable form, are stable to acids and alkalis and are capable of releasing the acid in the small and large intestines continuously over a long time.

7 cl, 5 dwg, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition for the reduction of a primary radiation response and an early transient incapacity containing ondansetron and gastrozepin in mass ratio 1-12:2-15; the composition is used as an injectable dosage form.

EFFECT: what is developed is the new composition.

3 cl, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to using probiotics in the manufacture of a drug or a therapeutic nutritional composition for long-term prevention of diarrhea in infants. Using the probiotic Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, and the probiotic Bifidobacterium longum ATCC BAA-999 in the manufacture of a drug or a therapeutic nutritional composition to be introduced into an infant for at least three months for the purpose of long-term prevention of diarrhoea, wherein the probiotic is introduced into a breastfeeding infant from a nursing mother.

EFFECT: using the above probiotic strains from the nursing mother is effective for the purpose of long-term prevention of diarrhoea in infants.

6 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, and aims at treating viral diseases in animals. What is declared is a composition for treating viral diseases in animals, containing two subtypes of vertebrate recombinant interferon mixed in equal molar proportions.

EFFECT: use of the declared composition enables ensuring the substantial increase of the therapeutic effect of recombinant interferons and minimising the potential adverse effects associated with their use.

4 ex

FIELD: medicine.

SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.

EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.

11 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.

EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.

12 cl, 5 tbl, 6 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry and deals with alimentation of children born by cesarean section. One proposes application of a composition including indigestible oligosaccharides to produce a composition for treatment and/or prevention of diseases with children born by cesarean section. The disease is selected from the group including asthma, allergy, infection and atopic dermatitis. Indigestible oligosaccharides content in the composition is 0.5 - 75 g per 100 g of dry weight of the composition. Alternatively the composition may include at least 5 wt % of indigestible oligosaccharides, at least 1 wt % of oligosaccharide consisting of uronic acid remains in terms of dry weight of the composition while total weight of indigestible oligosaccharides is 0.1 - 10 g per portion. Alternatively the composition may content 5-100 mg of nucleotides per 100 g of dry weight of the composition. Alternatively the composition may include 102 - 1013 CFU of bacteria per 1 g of dry weight of the composition.

EFFECT: invention allows to improve intestine maturation, enhance intestinal barrier and so to improve systemic condition of children born by caesarean section as well as promotes prevention and/or treatment of infection and other diseases with children born by caesarean section.

18 cl, 3 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula in which R1 and R2 independently denote C1-6alkyl; R4 denotes phenyl, substituted with trifluoromethyl if necessary; X denotes hydrogen or methyl; and Y denotes -C(O)R, where R denotes C1-6alkyl; or Y denotes -P(O)(OR5)2, where R5 denotes hydrogen or C1-6alkyl; or pharmaceutically acceptable salts thereof. Said compounds are prodrugs of adenosine A2B receptor. The invention also relates to a pharmaceutical composition which is an adenosine A2B receptor antagonist based on the compound of formula I.

EFFECT: formula I compounds and the pharmaceutical composition can be used in treating different diseases in mammals, such as gastrointestinal disorders, immunological disorders, allergic disorders, neurological disorders, cardiovascular disorders and diseases associated with cell hyperproliferation.

13 cl, 1 tbl, 15 ex

FIELD: chemistry.

SUBSTANCE: invention relates to medication, representing betulin bis-isonicotinoate .

EFFECT: low toxicity, expressed anti-ulcer, anti-inflammatory and hepatoprotective activity.

3 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a composition for treating anal fissures in the form of a hydrous gel, containing an active compound in the form of isosorbide dinitrate, a gelation agent, a neutralising agent and a solvent differing by the fact that the composition contains triethanolamine as the neutralising agent taken in equal proportions with the gelation agent which is presented by a lightly crosslinked polymer; the solvent is presented with a mixture of polyethyleneoxide and ethanol in ratio 5-6:1:3-4 with the ingredients of the composition taken in certain proportions, wt %.

EFFECT: invention provides higher clinical effectiveness and reduced length of treatment.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: what is used is botulinum toxin A in a dose of 20-35 Units administered into 4 points of 1, 5, 7 and 11 o'clock of the internal anal sphincter in a combination with subcutaneous administration of botulinum toxin 5-7 Units under the fissure from its distal end. Besides, a condition medium of mesenchymal stem cells in an amount of 20-30 ml is introduced into the rectum.

EFFECT: higher clinical effectiveness in the anal fissure and lower number of therapeutic injuries.

3 ex

FIELD: medicine.

SUBSTANCE: haemorrhoidectomy involving removing haemorrhoids en bloc with an anal wound closure is followed by daily dressings from the first postoperative day with using the antibacterial preparation Levomecol. That is combined with a therapeutic parenteral administration of standard analgesics and taking sitting baths and conducting a local physiotherapy. The preoperative preparation involves prescribing the complex immunomodulator Kipferon presented in the form of suppositories containing 500000 IU of interferon alpha-2 and 60 mg of complex immunoglobulin preparation. The preparation is administered in a dose of one suppository twice a day for 5 days preceding the haemorrhoidectomy. Then, administering the preparation is continued once a day in the same dose from the second to the eleventh postoperative day. The preoperative preparation is also added with prescribing the phlebotonic diosmin (Venarus, Detralex) orally in a dose of 500 mg twice a day for 3 days preceding the haemorrhoidectomy and continued in the same dose twice a day from the first to eighth postoperative day. Besides, from the second postoperative day the osmotic laxative Lactulose is administered orally in a dose of 15-25 ml once until the patient has an unassisted defecation.

EFFECT: lower postoperative post-defecation pain syndrome as estimated by VAS analogue scale, less manifested perianal tissue oedema within the operative tissues, shorter wound epithelisation as shown by a cytological pattern of impression smears, achieved adequate elimination of the postoperative complications in the form of bleedings, reflex urinary retention, formation of deforming adhesions, reduced bacterial content of the anal wounds, shorter time of patient's anal sphincter hypertonus, as well as adequate time of postoperative defecation recovery.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. What is presented is a probiotic composition containing a probiotic ingredient, which is presented by Bifidobacterium longum R175 and one or two bacterial species specified in a group consisting of Lactobacillus rhamnosus R11, Lactobacillus helveticus R52 and Lactobacillus plantarum R1012, and a carrier composition. The above carrier composition contains mixture of prebiotics containing inulin and fructose, lactoferrin, inorganic salts, and glutathione as possible. There are also presented versions of the compositions in certain ratio of the above ingredients. What is also presented is a version of the composition containing mixture of probiotic ingredients consisting of Bifidobacterium longum R175 and Lactobacillus rhamnosus R11, a prebiotic ingredient, lacroferrin, inorganic salts and Saccharomyces boulardii. The above compositions are used for supporting and/or recovering the intestinal health and for preventing disbiosis of any origin in mammals, as well as in a method for improving a survival rate of the bacteria Bifidobacterium longum in the gastrointestinal tract.

EFFECT: group of inventions provides the effective colonisation of the gastrointestinal tract with the probiotic ingredients, causes the accompanying anti-inflammatory and immunomodulatory action.

20 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition in the form of a coated retard tablet characterised by the fact that it contains a nucleus comprising a nucleus containing trimebutine maleate, microcrystalline cellulose, povidone, hypromellose, magnesium stearate, and a coating that represents Opadry II film (series 85) consisting of partially hydrolysed polyvinyl alcohol, macrogol-3550, titanium dioxide E 171 and talc powder with the ingredients of the composition taken in certain relations, mg.

EFFECT: invention provides storage-stability and high clinical effect.

2 cl, 3 ex

FIELD: agriculture.

SUBSTANCE: method of application of feed additive for pigs, comprising lactic ferment based on consortium of live lactic acid and propionic acid bacteria of three complexes: the 1st of strains of lactic acid bacteria S. salivarius-LT-1, S. Thermophilus-LT9, LT10, LT11 and strain of propionic acid bacteria Propionibacterium freidenreichii-LT8 in the ratio of 1:3; 2nd of strains of lactic acid bacteria L. Plantarum-LT7, L. Acidophilus-LT12 and strain of propionic acid bacteria Propionibacterium freidenreichii-LT8 in the ratio of 2:1; 3rd of the strains of propionic acid bacteria Propionibacterium freidenreichii-LT8 and lactic acid bacteria S. salivarius-LT-1, L. Plantarum-LT7, S. Thermophilus-LT9, LT10, LT11, L. Acidophilus-LT12 in a ratio of 7:2, which is then used for fermenting pasteurized milk with fat content of 1.5-2.5% and a ratio of 1:30, and the additive is daily fed together with the combined feed, in addition the minerals are periodically added to the composition of the feed additive: potassium iodide - KI and sodium selenite - Na2SeO3, adding is carried out after every day of omission, alternating with potassium iodide and sodium selenite weekly during the fattening period, starting with the four months of age of the piglets, and potassium iodide is added in an amount of 0.46 mg and sodium selenite - in an amount of 0.44 mg, i.e. 0.2 mg of pure selenium, per 1 kg of dry matter of diet.

EFFECT: increase in live body weight due to increase in muscle tissue, improving the quality of meat by reducing the layer of subcutaneous fat, increase in total body resistance to diseases of pigs.

8 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent containing activated-potentiated forms of anti-histamine, anti-tumour necrosis factor alpha (anti-TNF - α) and anti-S-100 brain specific antibodies is administered.

EFFECT: treating functional bowel disorders by ensuring the spasmolytic action and normalising the motor-evacuation function of the intestine.

11 cl, 4 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to an injection medical composition for local application in treatment of haemorrhoid, which contains hydroxychloroquine. In particular, the composition contains hydroxychloroquine in a physiological solution for injection with a local anaesthetic and an antioxidant.

EFFECT: injection composition by the invention ensures strengthening of haemorrhoid tissue for blocking metabolism in the haemorrhoid tissue, and as a result -necrosis of the haemorrhoid tissue.

5 cl, 8 dwg, 1 ex

Novel application // 2530567

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and deals with a preparation for the prevention of an inflammatory disease of the intestine, which represents galactooligosaccharide, which has a degree of polymerisation 3 or higher, selected from the group, consisting of trisaccharides Gal(β 1-6)-Gal(β 1-4)-Glc, Gal(β 1-3)-Gal(β 1-4)-Glc, tetrasaccharide Gal(β 1-6)-Gal(β 1-6)-Gal(β 1-4)-Glc and pentasaccharide Gal(β 1-6)-Gal(β 1-6)-Gal(β 1-6)-Gal(β 1-4)-Glc; application of the claimed galactooligosaccharide for the prevention of the inflammatory disease of the intestine; a method of preventing the inflammatory disease of the intestine, which includes peroral introduction to a mammal of an effective quantity of galactooligosaccharide.

EFFECT: group of inventions provide the powerful anti-inflammatory effect with respect to the inflammatory diseases of the intestine.

10 cl, 9 dwg, 4 ex

FIELD: nanotechnology.

SUBSTANCE: invention relates to the technology of electroforming nanofibres with a diameter not exceeding 500 nm, and the processes occurring in forming nanofibres in the chamber of the forming device. The invention relates to preparing the forming solution to produce nanofibres from aliphatic copolyamides, and methods of modifying nanofibres through various compositions of forming solution. Improvement of consumer properties of products based on the nanofibres is connected with diameter of the nanofibres obtained and with the surface morphology, or the substantial reduction in defects both of nanofibres and the material produced from them. When using the material based on nanofibres from aliphatic copolyamides it is necessary to provide bio-inertness and nontoxicity when in contact with body tissues, and also the possibility of biodegrading and recycling.

EFFECT: invention provides production of fibres with improved physical-chemical properties, which, in turn, improves significantly the product quality.

32 cl, 18 dwg, 2 tbl

Up!